Histologic and systemic prognosticators for local control and survival in margin-negative transoral laser microsurgery treated oral cavity squamous cell carcinoma

Head and Neck

Volumn 37, Issue 1, 2015, Pages 52-63

  Sinha, Parul ^a   Mehrad, Mitra ^a   Chernock, Rebecca D ^a   Lewis, James S ^a   El Mofty, Samir K ^a   Wu, Ningying ^a   Nussenbaum, Brian ^a   Haughey, Bruce H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brandwein Gensler score risk model; Immune compromise; Local control; Oral carcinoma; Transoral laser microsurgery (TLM)

Indexed keywords

ADULT; AGED; BRANDWEIN GENSLER SCORE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; LASER SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSURGERY; MOUTH SQUAMOUS CELL CARCINOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PROSPECTIVE STUDY; REFERENCE DATABASE; SCORING SYSTEM; TRANSORAL LASER MICROSURGERY; TUMOR IMMUNITY; TUMOR RECURRENCE; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; LOW LEVEL LASER THERAPY; MIDDLE AGED; MORTALITY; MOUTH NEOPLASMS; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LASER THERAPY; MALE; MICROSURGERY; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84918827787     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23553     Document Type: Conference Paper

References (44)

1. Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-Perez J, Rodriguez-Campo FJ. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck 2009;31:1168-1180.
2. Iseli TA, Lin MJ, Tsui A, Guiney A, Wiesenfeld D, Iseli CE. Are wider surgical margins needed for early oral tongue cancer? J Laryngol Otol 2012;126:289-294.
3. Rennemo E, Zatterstrom U, Boysen M. Outcome of local failures after oral cancer-recurrence vs. second primary. J Oral Pathol Med 2010;39:657-661.
4. Sutton DN, Brown JS, Rogers SN, Vaughan ED, Woolgar JA. The prognostic implications of the surgical margin in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2003;32:30-34.
5. Sessions DG, Spector GJ, Lenox J, Haughey BH, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope 2002; 112: 616-625.
6. Kurita H, Nakanishi Y, Nishizawa R, et al. Impact of different surgical margin conditions on local recurrence of oral squamous cell carcinoma. Oral Oncol 2010;46:814-817.
7. Byers RM, Bland KI, Borlase B, Luna M. The prognostic and therapeutic value of frozen section determinations in the surgical treatment of squamous carcinoma of the head and neck. Am J Surg 1978;136:525-528.
8. Chen TY, Emrich LJ, Driscoll DL. The clinical significance of pathological findings in surgically resected margins of the primary tumor in head and neck carcinoma. Int J Radiat Oncol Biol Phys 1987;13:833-837.
9. Spiro RH, Guillamondegui O Jr, Paulino AF, Huvos AG. Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 1999;21:408-413.
10. Jones AS. Prognosis in mouth cancer: tumour factors. Eur J Cancer B Oral Oncol 1994;30B:8-15.
11. Loree TR, Strong EW. Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 1990;160:410-414.
12. Slootweg PJ, Hordijk GJ, Schade Y, van Es RJ, Koole R. Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol 2002;38:500-503.
13. Rogers SN, Brown JS, Woolgar JA, et al. Survival following primary surgery for oral cancer. Oral Oncol 2009;45:201-211.
14. Sinha P, Hackman T, Nussenbaum B, Wu N, Lewis JS Jr, Haughey BH. Transoral laser microsurgery for oral squamous cell carcinoma: oncologic outcomes and prognostic factors. Head Neck 2013. [Epub ahead of print]
15. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005;29:167-178.
16. Vered M, Dayan D, Dobriyan A, et al. Oral tongue squamous cell carcinoma: recurrent disease is associated with histopathologic risk score and young age. J Cancer Res Clin Oncol 2010;136:1039-1048.
17. Vered M, Dobriyan A, Dayan D, et al. Tumor-host histopathologic variables, stromal myofibroblasts and risk score, are significantly associated with recurrent disease in tongue cancer. Cancer Sci 2010;101:274-280.
18. Brandwein-Gensler M, Smith RV, Wang B, et al. Validation of the histologic risk model in a new cohort of patients with head and neck squamous cell carcinoma. Am J Surg Pathol 2010;34:676-688.
19. Li Y, Bai S, Carroll W, et al. Validation of the risk model: high-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma. Head Neck Pathol 2013;7: 211-223.
20. Charazinska-Carewicz K, Ganowicz E, Krol M, Gorska R. Assessment of the peripheral immunocompetent cells in patients with reticular and atrophic-erosive lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:202-205.
21. Altundag O, Gullu I, Altundag K, et al. Induction chemotherapy with cis-platin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck 2005;27:15-21.
22. Prestwich RJ, Errington F, Hatfield P, et al. The immune system-is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008;20:101-112.
23. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992;18:187-201.
24. Young GP, Dudley FJ, Van Der Weyden MB. Suppressive effect of alcoholic liver disease sera on lymphocyte transformation. Gut 1979;20:833-839.
25. Braakhuis BJ, Bloemena E, Leemans CR, Brakenhoff RH. Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol 2010;46:485-491.
26. Hoşal AS, Unal OF, Ayhan A. Possible prognostic value of histopathologic parameters in patients with carcinoma of the oral tongue. Eur Arch Otorhi-nolaryngol 1998;255:216-219.
27. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24:95-105.
28. Wolf GT, Lovett EJ III, Peterson KA, Beauchamp ML, Baker SR. Lympho-kine production and lymphocyte subpopulations in patients with head and neck squamous carcinoma. Arch Otolaryngol 1984;110:731-735.
29. Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg 1994;120:395-403.
30. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 2003;3:1061-1071.
31. Penn I. Depressed immunity and the development of cancer. Clin Exp Immunol 1981;46:459-474.
32. Pumhirun P, Wasuwat P. Anergy testing in patients with head and neck cancer. Asian Pac J Allergy Immunol 2003;21:189-192.
33. Wu CH, Wu TY, Li CC, Lui MT, Chang KW, Kao SY. Impact of diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma: a retrospective cohort study. Ann Surg Oncol 2010;17:2175-2183.
34. Goutzanis L, Vairaktaris E, Yapijakis C, et al. Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway. Oral Oncol 2007;43:165-173.
35. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856-862.
36. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-1687.
37. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007;50:1365-1374.
38. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepa-tology 1998;28:921-925.
39. Davidson HC, Leibowitz MS, Lopez-Albaitero A, Ferris RL. Immunother-apy for head and neck cancer. Oral Oncol 2009;45:747-751.
40. Thomas DW, Seddon SV, Shepherd JP. Systemic immunosuppression and oral malignancy: a report of a case and review of the literature. Br J Oral Maxillofac Surg 1993;31:391-393.
41. Brookes GB, Clifford P. Nutritional status and general immune competence in patients with head and neck cancer. J R Soc Med 1981; 74: 132-139.
42. Fernandes G, West A, Good RA. Nutrition, immunity, and cancer-a review. Part III: effect of diet on the diseases of aging. Clin Bull 1979;9: 91-106.
43. Hinni ML, Zarka MA, Hoxworth JM. Margin mapping in transoral surgery for head and neck cancer. Laryngoscope 2013;123:1190-1198.
44. Hinni ML, Ferlito A, Brandwein-Gensler MS, et al. Surgical margins in head and neck cancer: a contemporary review. Head Neck 2013;35:1362-1370.